Tuesday 16 August 2022 - 03:15
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
D-3700 Dacomitinib, Free Base, >99%
Synonyms : [PF00299804] [PF299] [PF299804]
Related Terms : [Vizimpro]

- Size
- US $
- €
- £
- ¥
- 25 mg
- 37
- 36
- 30
- 4,900
- In stock
- 50 mg
- 43
- 42
- 35
- 5,700
- In stock
- 100 mg
- 67
- 65
- 55
- 8,900
- In stock
- 200 mg
- 98
- 96
- 81
- 13,000
- In stock
- 250 mg
- 119
- 116
- 98
- 15,800
- In stock
- 500 mg
- 207
- 202
- 171
- 27,500
- In stock
- 1 g
- 379
- 371
- 313
- 50,300
- In stock
- 2 g
- 590
- 578
- 487
- 78,300
- In stock
- 5 g
- 1,250
- 1,225
- 1,033
- 165,800
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 469.94
- C24H25ClFN5O2
- [1110813-31-4]
- Dacomitinib, also known as PF-00299804, is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. It irreversibly blocked erbB1 autophosphorylation in A431 human squamous carcinoma cells with an IC50 of 15.1 nM. It had significant antitumor activity in vivo, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) associated with resistance to gefitinib and erlotinib. Gonzales A.J., et al. "Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor." Mol. Cancer Ther. 7: 1880-1889 (2008).
- A phase 2 clinical trial demonstrated that dacomitinib had clinical activity in recurrent/metastatic squamous-cell carcinoma of the head and neck (RM-SCCHN). Its toxicity was generally manageable with dose adjustments and interruptions. Abdul Razak A.R., et al. "A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck." Ann. Oncol. 24: 761-769 (2013).
- A phase 2 clinical trial demonstrated that dacomitinib significantly improved progression-free survival (PFS) versus erlotinib with acceptable toxicity in patients with advanced non-small-cell lung cancer. PFS benefit was shown in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants. Ramalingam S.S., et al. "Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer." J. Clin. Oncol. 30: 3337-3344 (2012).
- Related CAS numbers: 1042385-75-0 for the hydrate (1:1).
- Dacomitinib is the active ingredient in the drug product sold under the trade name Vizimpro®. This drug is currently approved in at least one country for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor. NOTE: THE DACOMITINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT VIZIMPRO®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.